In Vitro Activities of Six New Fluoroquinolones against Brucella melitensis

Abstract

We have tested the in vitro activities of eight fluoroquinolones against 160 Brucella melitensis strains. The most active was sitafloxacin (MIC at which 90% of the isolates are inhibited [MIC90], 0.12 μg/ml). In decreasing order, the activities (MIC90s) of the rest of the tested fluoroquinolones were as follows: levofloxacin, 0.5 μg/ml; ciprofloxacin, trovafloxacin, and moxifloxacin, 1 μg/ml; and ofloxacin, grepafloxacin, and gatifloxacin, 2 μg/ml.

Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen

“…The efficacy of fluoroquinolones in the treatment of brucellosis has been shown both in vitro and in vivo [45]. Although most studies failed to prove the efficacy of quinolones as monotherapy for brucellosis [46], their inclusion in combination regimens is an accepted, though significantly more expensive, variation of the classical treatment [47,48].…”

Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection

“…The efficacy of two recent-generation fluoroquinolones, moxifloxacin and gatifloxacin, against Brucella spp. has been determined in vitro in a number of studies that include reported MIC 90 values (minimum inhibitory concentration for 90% of the organisms) of 0.125 g/mL [2], 1 g/mL [3] or 8 g/mL [4] for moxifloxacin and 2 g/mL [3] or 4 g/mL [5] for gatifloxacin. In one study, the MIC 90 values for moxifloxacin and gatifloxacin against 160 strains of Brucella melitensis were found to be 1 g/mL and 2 g/mL, respectively [3], highlighting the efficacy of the antibiotics against a wide range of strains.…”

In vitro antimicrobial susceptibility of Brucella species

“…As Brucella species are intracellular pathogens, the treatment requires not only combined regimens but agents that may efficiently penetrate macrophages as well [2,3]. The type of antibiotics used for treatment of brucellosis influences the recurrence rate and it is clear that a synergistic combination with marked intracellular activity is the best therapeutic regimen in Brucellosis [4].…”